AnDiConBio
Latest round
- Series A
Last raised
- Sep 2025
Total raised
- $28M
Investors
- 12
About AnDiConBio
Established in 2018 and based in Jiaxing, China, AnDiConBio is a biotech firm focusing on respiratory anti-infection and pain management. With a team of fewer than 50 employees, AnDiCon Bio is helmed by Dr. Wei Ping Jiang, who has an extensive background in the field. The company's core team comprises scientists with international perspectives and expertise in drug discovery and development. The company is dedicated to the research and development of novel drugs for respiratory infections. The company's portfolio includes treatments for influenza, COVID-19, and other respiratory diseases. Notable products include the oral anti-influenza drug ADC189 and the oral anti-COVID drug CN-2021, as well as Marduxanoxavir, a cap-dependent nucleic acid endonuclease inhibitor designed and developed in-house, which are designed to provide treatment options for patients with these conditions. The company generates revenue by providing innovative pharmaceutical solutions and advancing its pipeline of anti-infection drugs.
Who invested in AnDiConBio
12 investors across 2 rounds
See all investors in AnDiConBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about AnDiConBio
Who invested in AnDiConBio?
AnDiConBio has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AnDiConBio raised?
AnDiConBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did AnDiConBio last raise money?
AnDiConBio's most recent round on record is a Series A, in Sep 2025.
What does AnDiConBio do?
Established in 2018 and based in Jiaxing, China, AnDiConBio is a biotech firm focusing on respiratory anti-infection and pain management.
Where is AnDiConBio headquartered?
AnDiConBio is headquartered in Jiaxing, China.
Which VCs invest in companies like AnDiConBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at AnDiConBio's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like AnDiConBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.